Key result
Adenosine leads acute management of pediatric AVRT while beta-blockers remain preferred for chronic therapy.
Population
Children with atrioventricular reentrant tachycardia (AVRT)
Design
Review
Authors
Loading...
Reinforces standard acute and chronic strategies for pediatric AVRT; leaves open need for randomized trials to strengthen recommendations.
Adenosine is recommended for acute management of AVRT in children, while beta-blockers are preferred for chronic management, with specific contraindications for other antiarrhythmics based on age and structural heart disease.
Ratnasamy et al. (2008) conducted a review in Atrioventricular reentrant tachycardia (AVRT). Pharmacological therapy was evaluated. Adenosine is the drug of choice for acute management of atrioventricular reentrant tachycardia in children, while beta-blockers are the preferred first-line drugs for chronic management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: